Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
| Conditions: | Malignant Mesothelioma |
| Start Date: | July 1, 2001 |
| Phase: | Phase II |
| Status: | Completed |
| NCT ID: | NCT00017186 |
| Study Type: | Interventional |
| Intervention: | Drug: epirubicin hydrochloride|Drug: gemcitabine hydrochloride |
| Study Design: | Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | North Central Cancer Treatment Group|National Cancer Institute (NCI) |
| Ages: | Adult|Senior |
| Enrollment: | 0 |
| Funded By: | Other|NIH |
| First Received: | June 6, 2001 |
| End Date: | |
| Last Updated: | July 23, 2008 |
| Last Verified: | June 1, 2006 |
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
